Subscribe to RSS
DOI: 10.1055/s-0030-1254105
© Georg Thieme Verlag KG Stuttgart · New York
Pregabalin and Edema in Young Women Suffering from Premenstrual Syndrome
Publication History
received 05.10.2009
revised 10.02.2010
accepted 05.03.2010
Publication Date:
25 May 2010 (online)

Introduction
Pregabalin (PGB) is an antiepileptic drug that is also approved for neuropathic pain and for the treatment of generalized anxiety disorder (GAD) [1] [3] [8] [9]. PGB is a GABA analogue that is reported to have mild side effects including transient dizziness, somnolence, dry mouth and ataxia [14]. Edemas are reported to occur in up to 8% of the treated patients but only in higher doses [7]. In the literature to date, there are only two reports on PGB-related edema [12] [15], one of them caused by withdrawal of the drug [12] and one observed with medium dosages of PGB [15]. The authors of the latter case report conclude, however, that edema with PGB treatment may be self-limited, transient and therefore not frequently found. We report here on three cases of severe and persistent edema in young females with GAD and a history of premenstrually-related cyclic edema, one of which was succesfully treated with a new oral contraceptive regimen.
References
- 1 Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 2007; 7 769-781
- 2 Bekheirnia MR, Schrier RW. Pathophysiology of water and sodium retention: edematous status with normal kidney function. Curr Opin Pharmacol. 2006; 6 202-207
- 3 Beydoun A, Uthman BM, Kugler AR. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005; 64 475-480
- 4 Bursaux CD, Paris J, Pintiaux C. et al . Premenstrual syndrome and its treatment The role of progestagens. Rev FR Gynecol Obstet. 1985; 80 753-762
-
5
Die Lithiumtherapie: Nutzen, Risiken, Alternativen, Müller-Oerlinghausen B et al. (Eds.), 2 nd edn, Springer, Berlin, Heidelberg
1997;
- 6 Ellison DH, Berl T. Clinical practice: The syndrome of inappropriate antidiuresis. NEJM. 2007; 356 2064-2072
- 7 Freeman R, Durso-Decruz E, Emir B. Efficacy, safety and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes care. 2008; 31 1448-1445
- 8 French J, Kugler A, Robbins J. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003; 60 1631-1637
- 9 Hamandi K, Sander JW. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure. 2006; 15 73-78
- 10 Hernadi L, Marr J, Trummer D. et al . Efficacy and saftey of a low dose combined oral contraceptive containing drospirenone 3 mg and ethinyestradiol 20 mcg in a 24/4 day regimen. Contraception. 2009; 80 18-24
- 11 Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol. 1987; 30 367-376
- 12 Prilipko O, Delavelle J, Seeck M. Pregabalin-withdrawal encephalopathy an splenial edema. Ann Neurol. 2006; 59 214
- 13 Schroth BE. Evaluation and management of peripheral edema. JAAPA. 2005; 18 29-34
- 14 Selak I. Pregabalin. Curr Opinion Investig Drugs. 2001; 2 828-834
- 15 Wustman T, Piro J, Gutman P. Metabolic considerations in a case of pregablin induced edema. Pharmacopsychiatry. 2009; 42 75-76
- 16 Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf. 2009; 32 735-748
Correspondence
Prof. Dr. med. S. Krüger
Klinik und Poliklinik für Psychiatrie und Psychotherapie
Charité Campus Mitte
Charitéplatz 1
10117 Berlin
Germany
Phone: +49/30/450 517094
Fax: +49/30/450 517177
Email: stephanie.krueger@charite.de